Humana to Divest Stake in Gentiva for $900 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Source: NASDAQ.COM
- Equity Sale Agreement: Humana has entered into a definitive agreement with a consortium of investors to divest all or substantially all of its minority interest in Gentiva, valuing the stake at approximately $900 million, indicating a strategic intent to optimize asset allocation.
- Clear Use of Proceeds: The proceeds from this transaction will be used for general corporate purposes, demonstrating Humana's strategy to enhance financial flexibility through asset disposals to support future business growth.
- Transaction Timeline: The deal is expected to close in the third quarter of 2026, with Humana not anticipating a material impact on its 2026 earnings, reflecting confidence in the company's future financial stability.
- Gentiva Business Context: Gentiva provides end-of-life and palliative care services, and Humana's divestiture may influence its strategic positioning in the healthcare sector, particularly in the competitive landscape of elder care services.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HUM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HUM
Wall Street analysts forecast HUM stock price to fall
19 Analyst Rating
6 Buy
12 Hold
1 Sell
Moderate Buy
Current: 368.690
Low
231.00
Averages
290.39
High
344.00
Current: 368.690
Low
231.00
Averages
290.39
High
344.00
About HUM
Humana Inc. provides Humana insurance services and CenterWell health care services. The Company's segments include Insurance and CenterWell. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as its contract with CMS to administer the Limited Income Newly Eligible Transition (LI-NET) prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups. The CenterWell segment includes its pharmacy, primary care, and home solutions operations. The segment also includes its strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as its minority ownership interest in hospice operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Humana Stock Shows Signs of Overbought Risk
- Stock Performance Review: Humana's stock has more than doubled since the market bottomed during the U.S.-Iran war on March 30, yet it was identified as one of the overbought stocks in the S&P 500 by the end of the week, indicating potential downside risk.
- Market Volatility Analysis: Despite choppy trading in major U.S. indexes over the past five sessions, the S&P 500 managed to rise for the 10th time in 11 weeks, reflecting complex investor sentiment influenced by geopolitical developments and the SpaceX IPO.
- Healthcare Sector Resilience: UBS noted that the healthcare sector outperformed the S&P 500 on 85% of the days when the benchmark fell by 1% or more over the past year, demonstrating the sector's resilience amid market turbulence.
- Analyst Rating Adjustments: Bank of America raised its price target for J.M. Smucker to $132, implying about a 14% potential upside from Friday's close, reflecting optimistic market expectations for the company's future performance.
See More
Humana to Divest Stake in Gentiva for $900 Million
- Equity Sale Agreement: Humana has entered into a definitive agreement with a consortium of investors to divest all or substantially all of its minority interest in Gentiva, valuing the stake at approximately $900 million, indicating a strategic intent to optimize asset allocation.
- Clear Use of Proceeds: The proceeds from this transaction will be used for general corporate purposes, demonstrating Humana's strategy to enhance financial flexibility through asset disposals to support future business growth.
- Transaction Timeline: The deal is expected to close in the third quarter of 2026, with Humana not anticipating a material impact on its 2026 earnings, reflecting confidence in the company's future financial stability.
- Gentiva Business Context: Gentiva provides end-of-life and palliative care services, and Humana's divestiture may influence its strategic positioning in the healthcare sector, particularly in the competitive landscape of elder care services.
See More
Humana to Divest Minority Stake in Gentiva for $900 Million
- Agreement Signed: Humana has signed a definitive agreement with a consortium of investors to divest its minority stake in Gentiva, valued at approximately $900 million, with the transaction expected to close in Q3 2026, and the company does not anticipate a material impact on 2026 earnings from this pending transaction.
- Business Restructuring Context: Humana's ownership in Gentiva stems from its acquisition of the remaining interest in Kindred at Home in 2021, indicating the company's long-standing intention to divest non-core businesses, including hospice and personal health care services, to focus on its core insurance operations.
- Market Leadership: Gentiva, as the nation's largest provider of end-of-life services, operates over 430 locations with thousands of compassionate clinicians and caregivers, and Humana's divestiture will allow it to concentrate on enhancing the quality and efficiency of its insurance services.
- Advisory Support: Guggenheim Securities is acting as financial advisor to Humana, ensuring the smooth execution of the transaction, while the legal advisory team includes Fried, Frank, Harris, Shriver & Jacobson LLP and Manatt, Phelps & Phillips LLP, further enhancing the compliance and security of the deal.
See More
Humana Foundation's Double Match Day Raises Funds and Grants
- Fundraising Achievement: During the Humana Foundation's Double Match Day, over 1,600 employees donated more than $1.4 million in just 24 hours to support 1,650 nonprofits, showcasing strong employee engagement and commitment to community support.
- Matching Donation Mechanism: Since 2022, Humana and its foundation have contributed a total of $5.9 million in matching donations during Double Match Day, reflecting the company's ongoing commitment to enhancing employee charitable contributions and their impact.
- Employee Incentives and Grants: The foundation awarded a total of $45,000 in grants to participating employees, including one employee receiving $25,000, which further incentivizes staff to actively engage in community service initiatives.
- Cultural and Value Reflection: Humana Foundation CEO Tiffany Benjamin emphasized that Double Match Day is not just a fundraising event but a reflection of the company's culture, demonstrating how employees unite to support causes they care about, promoting health equity and community well-being.
See More
Novo Nordisk and Eli Lilly Intensify Competition in Obesity Drug Market
- Prescription Milestone: Novo Nordisk announced that prescriptions for its Wegovy drug have surpassed 3 million in the U.S. market, indicating strong growth in the competitive GLP-1 drug market, even as Eli Lilly launched its own GLP-1 pill, Foundayo.
- New Medicare Opportunity: Starting in July, millions of Medicare beneficiaries will gain access to GLP-1 drugs for weight loss at $50 per month, significantly reducing the financial burden on patients and potentially boosting Wegovy's market share.
- New Drug Development Progress: At the conference, Lilly presented Phase 3 data for its experimental drug retatrutide, showing an average weight loss of 28% among patients, which could reshape the obesity treatment landscape, especially among individuals with higher BMIs.
- Future Product Strategy: Novo Nordisk plans to launch the CagriSema drug, although its efficacy has not surpassed Lilly's Zepbound, the company remains committed to diversifying its cardiometabolic health product line to address market competition and enhance its stock price.
See More
Novo Nordisk and Eli Lilly Compete in GLP-1 Market
- Intensifying Market Competition: Novo Nordisk's Wegovy has surpassed 3 million prescriptions since its U.S. launch five months ago, while Eli Lilly's Foundayo has seen a significant increase in prescriptions following its first-quarter report, highlighting fierce competition in the weight loss drug market.
- New Medicare Coverage Opportunity: Starting July 1, millions of seniors will gain access to GLP-1 drugs for weight loss at $50 per month, significantly reducing the financial burden on patients and providing both companies with an opportunity to expand their market share.
- Product Advantage Promotion: Novo Nordisk plans to emphasize the cardiovascular protective benefits of Wegovy to attract senior patients, while Eli Lilly focuses on the convenience of Foundayo, showcasing differing marketing strategies between the two companies.
- New Drug Development Progress: Lilly presented Phase 3 data for retatrutide at the conference, showing an average weight loss of 28% among patients, while Novo Nordisk anticipates FDA approval for CagriSema, despite its efficacy not surpassing that of competitors' products.
See More
Humana Stock Shows Signs of Overbought Risk
- Stock Performance Review: Humana's stock has more than doubled since the market bottomed during the U.S.-Iran war on March 30, yet it was identified as one of the overbought stocks in the S&P 500 by the end of the week, indicating potential downside risk.
- Market Volatility Analysis: Despite choppy trading in major U.S. indexes over the past five sessions, the S&P 500 managed to rise for the 10th time in 11 weeks, reflecting complex investor sentiment influenced by geopolitical developments and the SpaceX IPO.
- Healthcare Sector Resilience: UBS noted that the healthcare sector outperformed the S&P 500 on 85% of the days when the benchmark fell by 1% or more over the past year, demonstrating the sector's resilience amid market turbulence.
- Analyst Rating Adjustments: Bank of America raised its price target for J.M. Smucker to $132, implying about a 14% potential upside from Friday's close, reflecting optimistic market expectations for the company's future performance.
See More
Humana to Divest Stake in Gentiva for $900 Million
- Equity Sale Agreement: Humana has entered into a definitive agreement with a consortium of investors to divest all or substantially all of its minority interest in Gentiva, valuing the stake at approximately $900 million, indicating a strategic intent to optimize asset allocation.
- Clear Use of Proceeds: The proceeds from this transaction will be used for general corporate purposes, demonstrating Humana's strategy to enhance financial flexibility through asset disposals to support future business growth.
- Transaction Timeline: The deal is expected to close in the third quarter of 2026, with Humana not anticipating a material impact on its 2026 earnings, reflecting confidence in the company's future financial stability.
- Gentiva Business Context: Gentiva provides end-of-life and palliative care services, and Humana's divestiture may influence its strategic positioning in the healthcare sector, particularly in the competitive landscape of elder care services.
See More
Humana to Divest Minority Stake in Gentiva for $900 Million
- Agreement Signed: Humana has signed a definitive agreement with a consortium of investors to divest its minority stake in Gentiva, valued at approximately $900 million, with the transaction expected to close in Q3 2026, and the company does not anticipate a material impact on 2026 earnings from this pending transaction.
- Business Restructuring Context: Humana's ownership in Gentiva stems from its acquisition of the remaining interest in Kindred at Home in 2021, indicating the company's long-standing intention to divest non-core businesses, including hospice and personal health care services, to focus on its core insurance operations.
- Market Leadership: Gentiva, as the nation's largest provider of end-of-life services, operates over 430 locations with thousands of compassionate clinicians and caregivers, and Humana's divestiture will allow it to concentrate on enhancing the quality and efficiency of its insurance services.
- Advisory Support: Guggenheim Securities is acting as financial advisor to Humana, ensuring the smooth execution of the transaction, while the legal advisory team includes Fried, Frank, Harris, Shriver & Jacobson LLP and Manatt, Phelps & Phillips LLP, further enhancing the compliance and security of the deal.
See More
Humana Foundation's Double Match Day Raises Funds and Grants
- Fundraising Achievement: During the Humana Foundation's Double Match Day, over 1,600 employees donated more than $1.4 million in just 24 hours to support 1,650 nonprofits, showcasing strong employee engagement and commitment to community support.
- Matching Donation Mechanism: Since 2022, Humana and its foundation have contributed a total of $5.9 million in matching donations during Double Match Day, reflecting the company's ongoing commitment to enhancing employee charitable contributions and their impact.
- Employee Incentives and Grants: The foundation awarded a total of $45,000 in grants to participating employees, including one employee receiving $25,000, which further incentivizes staff to actively engage in community service initiatives.
- Cultural and Value Reflection: Humana Foundation CEO Tiffany Benjamin emphasized that Double Match Day is not just a fundraising event but a reflection of the company's culture, demonstrating how employees unite to support causes they care about, promoting health equity and community well-being.
See More
Novo Nordisk and Eli Lilly Intensify Competition in Obesity Drug Market
- Prescription Milestone: Novo Nordisk announced that prescriptions for its Wegovy drug have surpassed 3 million in the U.S. market, indicating strong growth in the competitive GLP-1 drug market, even as Eli Lilly launched its own GLP-1 pill, Foundayo.
- New Medicare Opportunity: Starting in July, millions of Medicare beneficiaries will gain access to GLP-1 drugs for weight loss at $50 per month, significantly reducing the financial burden on patients and potentially boosting Wegovy's market share.
- New Drug Development Progress: At the conference, Lilly presented Phase 3 data for its experimental drug retatrutide, showing an average weight loss of 28% among patients, which could reshape the obesity treatment landscape, especially among individuals with higher BMIs.
- Future Product Strategy: Novo Nordisk plans to launch the CagriSema drug, although its efficacy has not surpassed Lilly's Zepbound, the company remains committed to diversifying its cardiometabolic health product line to address market competition and enhance its stock price.
See More
Novo Nordisk and Eli Lilly Compete in GLP-1 Market
- Intensifying Market Competition: Novo Nordisk's Wegovy has surpassed 3 million prescriptions since its U.S. launch five months ago, while Eli Lilly's Foundayo has seen a significant increase in prescriptions following its first-quarter report, highlighting fierce competition in the weight loss drug market.
- New Medicare Coverage Opportunity: Starting July 1, millions of seniors will gain access to GLP-1 drugs for weight loss at $50 per month, significantly reducing the financial burden on patients and providing both companies with an opportunity to expand their market share.
- Product Advantage Promotion: Novo Nordisk plans to emphasize the cardiovascular protective benefits of Wegovy to attract senior patients, while Eli Lilly focuses on the convenience of Foundayo, showcasing differing marketing strategies between the two companies.
- New Drug Development Progress: Lilly presented Phase 3 data for retatrutide at the conference, showing an average weight loss of 28% among patients, while Novo Nordisk anticipates FDA approval for CagriSema, despite its efficacy not surpassing that of competitors' products.
See More
